Bogle Investment Management’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Bogle Investment Management’s Portfolio BSTC Stock Details BSTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-14,700	Closed	-$916K	–	365
2019 Q1	$916K	Buy	+14,700	New	+$972K	0.07%	205
2016 Q3	–	Sell	-34,543	Closed	-$1.38M	–	487
2016 Q2	$1.38M	Buy	34,543 +14,013	+68%	+$513K	0.1%	217
2016 Q1	$714K	Buy	+20,530	New	+$753K	0.05%	300
2015 Q4	–	Sell	-55,541	Closed	-$2.42M	–	465
2015 Q3	$2.42M	Buy	+55,541	New	+$3M	0.17%	158
2015 Q1	–	Sell	-33,180	Closed	-$1.28M	–	441
2014 Q4	$1.28M	Buy	+33,180	New	+$1.27M	0.09%	244

Other funds holding BSTC

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bogle Investment Management's BSTC Position: Q2 2019 in Review

Bogle Investment Management sold out of BioSpecifics Technologies Corp. (BSTC) in Q2 2019, closing a stake of 14,700 shares — an estimated $916K sold.

Bogle Investment Management first reported a position in BSTC in Q4 2014 and held it in 5 quarters. The position peaked at $2.42M in Q3 2015. 114 funds tracked by Wall St. Rank hold BSTC as of Q2 2019.

Bogle Investment Management reported no remaining BioSpecifics Technologies Corp. position as of Q2 2019 after selling out during the quarter.
Bogle Investment Management sold 14,700 BioSpecifics Technologies Corp. shares in Q2 2019, an estimated $916K.
Bogle Investment Management first reported a position in BioSpecifics Technologies Corp. in Q4 2014 and held it in 5 quarters.
Bogle Investment Management's BioSpecifics Technologies Corp. position peaked at $2.42M in Q3 2015.
114 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q2 2019.

Based on Bogle Investment Management's 13F filing for Q2 2019, filed 13 Aug 2019.